gliclazide has been researched along with c-peptide in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (17.65) | 18.7374 |
| 1990's | 16 (47.06) | 18.2507 |
| 2000's | 9 (26.47) | 29.6817 |
| 2010's | 1 (2.94) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Friedberg, SJ; Pugh, JA; Ramirez, G; Sawyer, J; Tuley, M; Wagner, ML | 1 |
| Borghi, VC; Giannella-Neto, D; Porrelli, RN; Santomauro, AT; Wajchenberg, BL | 1 |
| Aschner, P; Kattah, W | 1 |
| Cerasi, E; del Rio, G; Della Casa, L; Glaser, B | 1 |
| Argyraki, M; Broughton, D; Johnson, AB; Jones, IR; Miller, M; Taylor, R; Thow, JC | 1 |
| Gerich, JE; van der Veen, EA; van Haeften, TW; Veneman, TF | 1 |
| Batch, J; Bird, D; Cameron, D; Charles, B; Ma, A; Noble, R; Ravenscroft, P | 1 |
| Burnett, MA; Hosker, JP; Matthews, DR; Rudenski, AS; Turner, RC | 1 |
| Altomare, E; Di Reda, N; Giovine, A; Lasorsa, G; Procacci, V; Roberto, MG; Stufano, N; Vendemiale, G | 1 |
| Ceriello, A; Consoli, G; Giugliano, D; Quatraro, A | 1 |
| Bompiani, G; Bucalo, ML; Cerasola, GA; Donatelli, M; Giardina, E; Russo, V; Sinagra, D | 1 |
| Brogard, JM; Dorner, M; Pinget, M | 1 |
| Bodansky, HJ; Cudworth, AG; de Silva, RS; Medback, S; Rees, LH | 1 |
| Chow, CC; Cockram, CS; Sorensen, JP; Tsang, LW | 1 |
| Abiru, N; Akazawa, S; Ishibasi, M; Kawasaki, E; Matsumoto, K; Matsuo, H; Uotani, S; Yamamoto, H; Yamasaki, H; Yano, M | 1 |
| Chen, KW; Huang, BY; Huang, HS; Huang, MJ; Juang, JH; Lin, JD | 1 |
| Bjørbaek, C; Lund, S; Pedersen, O; Vestergaard, H | 1 |
| Awata, T; Inoue, I; Katayama, S; Negishi, K; Noji, S; Takahashi, K | 1 |
| Ambrosi, F; Filipponi, P; Gregorio, F; Manfrini, S; Santucci, A | 1 |
| Barrow, BA; Levy, JC; Manley, SE; Rachman, J; Turner, RC | 1 |
| Boland, O; Matthews, DR | 1 |
| Gedik, O; Güvener, N | 1 |
| Gomis, R; Jones, NP; Patwardhan, RN; Squatrito, S; Wolffenbuttel, BH | 1 |
| Chazan, AC; Gomes, MB | 1 |
| Bettio, M; da Tos, V; Del Prato, S; Maran, A; Marchetto, S; Marescotti, MC; Tadiotto, F; Tiengo, A; Vigili de Kreutzenberg, S | 1 |
| Ligtenberg, JJ; Reitsma, WD; van Haeften, TW | 1 |
| Hansen , AP; Juhl, CB; Pincus, SM; Pørksen, N; Schmitz, O; Veldhuis, JD | 1 |
| Brunetti, P; Charbonnel, BH; Hanefeld, M; Matthews, DR; Schernthaner, G | 1 |
| Brunetti, P; Charbonnel, B; Hanefeld, M; Matthews, DR; Schernthaner, G; Tan, MH; Urquhart, R | 1 |
| Chabraoui, L; Chebraoui, L; Chraibi, A; El Guessabi, L; Fellat, S; Israili, ZH; Lyoussi, B; M'guil, M; Ragala, MA | 1 |
| Ammini, AC; Chandra, ST; Dwivedi, S; Jyotsna, VP; Khurana, ML; Priya, G; Sreenivas, V | 1 |
| Ahmed, AA; Al-Rasheed, NM; Attia, HN; Kenawy, SA; Maklad, YA | 1 |
| Abdelkader, NF; Badawi, MA; Eitah, HE; Gamaleldin, AA; Kenawy, SA; Maklad, YA | 1 |
| Cordiner, RLM; Mari, A; Pearson, ER; Tura, A | 1 |
1 review(s) available for gliclazide and c-peptide
| Article | Year |
|---|---|
Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis.
Topics: Blood Glucose; C-Peptide; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; MEDLINE; Meta-Analysis as Topic; Middle Aged; Periodicals as Topic; Sulfonylurea Compounds; Tolazamide; Treatment Outcome; United States | 1992 |
18 trial(s) available for gliclazide and c-peptide
| Article | Year |
|---|---|
Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis.
Topics: Blood Glucose; C-Peptide; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; MEDLINE; Meta-Analysis as Topic; Middle Aged; Periodicals as Topic; Sulfonylurea Compounds; Tolazamide; Treatment Outcome; United States | 1992 |
The effect of sulphonylurea therapy on skeletal muscle glycogen synthase activity and insulin secretion in newly presenting type 2 (non-insulin-dependent) diabetic patients.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Fasting; Female; Gliclazide; Glycated Hemoglobin; Glycogen Synthase; Humans; Insulin; Insulin Secretion; Insulin, Regular, Pork; Male; Middle Aged; Muscles; Random Allocation; Recombinant Proteins | 1991 |
Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Sulfonylurea Compounds | 1986 |
Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fructosamine; Gliclazide; Glipizide; Glyburide; Glycated Hemoglobin; Hexosamines; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Treatment Failure; Triglycerides | 1995 |
Insulin response after treatment depends on fasting plasma glucose level in NIDDM.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Fasting; Female; Gliclazide; Glucagon; Glucose Tolerance Test; Glyburide; Humans; Insulin; Male; Middle Aged | 1994 |
Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.
Topics: Acarbose; Aged; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fasting; Gliclazide; Glucose Intolerance; Glycated Hemoglobin; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Middle Aged; Postprandial Period; Proinsulin; Time Factors; Tolbutamide; Triglycerides; Trisaccharides | 1997 |
Meformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study.
Topics: Blood Glucose; Body Constitution; Body Mass Index; C-Peptide; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Fatty Acids, Nonesterified; Female; Gliclazide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoprotein(a); Male; Metformin; Middle Aged; Regression Analysis; Sex Characteristics | 1997 |
Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
Topics: Adult; Aged; Arginine; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Fasting; Gliclazide; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Proinsulin | 1997 |
The stimulation of insulin secretion in non-insulin-dependent diabetic patients by amino acids and gliclazide in the basal and hyperglycemic state.
Topics: Aged; Arginine; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Female; Gliclazide; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Insulin Secretion; Leucine; Male; Middle Aged; Time Factors | 1997 |
Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients.
Topics: Acarbose; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Prospective Studies; Triglycerides | 1999 |
Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Fructosamine; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Triglycerides | 2000 |
Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Gliclazide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sulfonylurea Compounds; Treatment Failure | 2001 |
Mechanisms of acute and chronic hypoglycemic action of gliclazide.
Topics: Acute Disease; Blood Glucose; C-Peptide; Chronic Disease; Diabetes Mellitus, Type 2; Gliclazide; Gluconeogenesis; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Kinetics; Middle Aged; Placebos; Regression Analysis; Time Factors; Tritium | 2000 |
Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus.
Topics: Adult; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged | 2001 |
Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Entropy; Fatty Acids, Nonesterified; Gliclazide; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Middle Aged; Placebos; Prospective Studies; Time Factors | 2001 |
A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Gliclazide; Humans; Hypoglycemic Agents; Insulin; Lipids; Middle Aged; Pioglitazone; Proinsulin; Thiazolidinediones; Treatment Outcome | 2005 |
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Reproducibility of Results; Safety; Thiazolidinediones; Treatment Failure; Treatment Outcome | 2005 |
Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Treatment Outcome | 2008 |
16 other study(ies) available for gliclazide and c-peptide
| Article | Year |
|---|---|
Short- and long-term gliclazide effects on pancreatic islet cell function and hepatic insulin extraction in non-insulin-dependent diabetes mellitus.
Topics: Administration, Oral; Adult; Arginine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Gliclazide; Glucose; Glucose Tolerance Test; Humans; Injections, Intravenous; Insulin; Islets of Langerhans; Liver; Male; Middle Aged; Sulfonylurea Compounds; Time Factors | 1992 |
Effects of the combination of insulin and gliclazide compared with insulin alone in type 2 diabetic patients with secondary failure to oral hypoglycemic agents.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Eating; Fasting; Female; Gliclazide; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Middle Aged; Treatment Failure | 1992 |
Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Follow-Up Studies; Gliclazide; Glucose Clamp Technique; Humans; Insulin; Insulin Infusion Systems; Insulin Secretion; Middle Aged; Obesity | 1991 |
Influence of gliclazide on glucose-stimulated insulin release in man.
Topics: Adult; Blood Glucose; C-Peptide; Gliclazide; Glucose; Glucose Clamp Technique; Humans; Insulin; Male; Time Factors | 1991 |
The effects of ingestion time of gliclazide in relationship to meals on plasma glucose, insulin and C-peptide levels.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Food; Gliclazide; Humans; Insulin; Male; Middle Aged; Sulfonylurea Compounds; Time Factors | 1990 |
Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Gliclazide; Glucose Clamp Technique; Humans; Insulin; Islets of Langerhans; Kinetics; Middle Aged; Sulfonylurea Compounds | 1989 |
[Pharmacodynamics of second generation sulfonylureas: dose-effect curve of gliclazide in type 2 diabetes mellitus].
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Gliclazide; Glucose; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Sulfonylurea Compounds | 1988 |
Effect of prolonged gliclazide therapy in non-insulin dependent diabetic subjects.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Sulfonylurea Compounds; Time Factors | 1985 |
Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics.
Topics: Adult; Arginine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gliclazide; Glucagon; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Iodine Radioisotopes; Male; Middle Aged; Sulfonylurea Compounds; Time Factors | 1984 |
Long term improvement in insulin response with gliclazide treatment.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Female; Gliclazide; Humans; Insulin; Male; Middle Aged; Sulfonylurea Compounds | 1982 |
Effect of gliclazide on plasma lipids and pancreatic beta cell function in non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Islets of Langerhans; Lipids; Male; Middle Aged | 1993 |
Unchanged gene expression of glycogen synthase in muscle from patients with NIDDM following sulphonylurea-induced improvement of glycaemic control.
Topics: Adult; Aged; Animals; Base Sequence; Biopsy; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; DNA Primers; DNA, Complementary; Female; Gene Expression; Gliclazide; Globins; Glucose Clamp Technique; Glucose Tolerance Test; Glycogen Synthase; Humans; Hyperinsulinism; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Male; Middle Aged; Molecular Sequence Data; Muscle, Skeletal; Polymerase Chain Reaction; Rabbits; RNA, Messenger | 1995 |
Is Ramadan fasting safe in type 2 diabetic patients in view of the lack of significant effect of fasting on clinical and biochemical parameters, blood pressure, and glycemic control?
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; C-Peptide; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fasting; Female; Fructosamine; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Islam; Liver Function Tests; Male; Middle Aged; Morocco; Patient Education as Topic; Religion and Medicine; Risk Factors; Treatment Outcome; Triglycerides | 2008 |
Protective effects of combined therapy of gliclazide with curcumin in experimental diabetic neuropathy in rats.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Peptide; Curcumin; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Drug Therapy, Combination; Gabapentin; gamma-Aminobutyric Acid; Gliclazide; Hyperalgesia; Hypoglycemic Agents; Lipid Peroxides; Male; Pain Threshold; Peroxynitrous Acid; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha | 2012 |
New combination therapy of gliclazide and quercetin for protection against STZ-induced diabetic rats.
Topics: Animals; Blood Glucose; C-Peptide; Cholesterol; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Gliclazide; Glutathione; Hypoglycemic Agents; Inflammation; Insulin; Islets of Langerhans; Male; Malondialdehyde; NF-kappa B; Oxidative Stress; Pancreas; Quercetin; Rats; Rats, Wistar; Streptozocin; Superoxide Dismutase; Triglycerides; Tumor Necrosis Factor-alpha | 2020 |
The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Gliclazide; Glucose; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Proof of Concept Study | 2021 |